| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | temsirolimus | CTRPv2 | pan-cancer | AAC | -0.015 | 0.7 |
| mRNA | Vandetanib | CTRPv2 | pan-cancer | AAC | 0.011 | 0.7 |
| mRNA | BRD-K16130065 | CTRPv2 | pan-cancer | AAC | 0.022 | 0.7 |
| mRNA | erismodegib | CTRPv2 | pan-cancer | AAC | -0.012 | 0.7 |
| mRNA | BRD-K42260513 | CTRPv2 | pan-cancer | AAC | 0.017 | 0.8 |
| mRNA | BRD-K26531177 | CTRPv2 | pan-cancer | AAC | -0.011 | 0.8 |
| mRNA | BRD-K92856060 | CTRPv2 | pan-cancer | AAC | -0.011 | 0.8 |
| mRNA | SNX-2112:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.01 | 0.8 |
| mRNA | SU11274 | CTRPv2 | pan-cancer | AAC | -0.011 | 0.8 |
| mRNA | semagacestat | CTRPv2 | pan-cancer | AAC | 0.011 | 0.8 |